Lilly's Cyramza misses liver-cancer target

Eli Lilly's gastric cancer drug Cyramza, previously known as ramucirumab, failed to hit its Phase-III targets among liver-cancer patients using the drug as a second-line treatment. The Wall Street Journal reports that although Cyramza patients had more favorable overall survival rates than placebo patients, the differences were not statistically significant.

The drug failed to hit targets in a breast cancer clinical trial last year, but showed promise in Phase-III tests among non-small cell lung cancer patients when used with docetaxel.

You must be a registered member of MMM to post a comment.
close

Next Article in Channel

 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.